NSCLC
Crizotinib appears to be efficacious and well tolerated in patients with NSCLC and may have future potential applications in treating lymphomas and other cancers driven by ALK or c-MET gene mutations.
Crizotinib appears to be efficacious and well tolerated in patients with <span class="disease" id="23686600-9-73-78">NSCLC</span> and may have future potential applications in treating lymphomas and other cancers driven by <span class="gene" id="23686600-9-172-175">ALK</span> or c-MET gene mutations.